Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group

This publication has 15 references indexed in Scilit:

• Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
  Cancer, 2001
• Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
  Journal of Clinical Oncology, 2000
• Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
  Journal of Clinical Oncology, 2000
• Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial
  Journal of Clinical Oncology, 2000
• Use of aromatase inhibitors in breast carcinoma.
  Endocrine-Related Cancer, 1999
• Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
  Annals of Oncology, 1998
• Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
  Journal of Clinical Oncology, 1998
• First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer
  Annals of Oncology, 1996
• Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen
  Cancer, 1994
• Endocrine Therapy of Advanced Breast Cancer
  Acta Oncologica, 1988